These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 38329134)

  • 1. Direct-To-Definitive Urine and Oral Fluid Test Results for Unscreened and Rarely Screened Drugs in Individuals Applying for Methadone Treatment in 7 U.S. States.
    Lee-Easton MJ; Magura S; Abu-Obaid R; Reed P; Allgaier B; Fish E; Maletta A; Amaratunga P; Lorenz-Lemberg B; Levitas M; Achtyes E
    J Psychoactive Drugs; 2024 Feb; ():1-12. PubMed ID: 38329134
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparing presumptive with direct-to-definitive drug testing in oral fluid vs. urine for a U.S. national sample of individuals misusing drugs.
    Magura S; Lee-Easton MJ; Abu-Obaid R; Reed P; Allgaier B; Amaratunga P; Lorenz-Lemberg B; Levitas M; Achtyes ED
    Drug Alcohol Depend; 2023 Sep; 250():110894. PubMed ID: 37481872
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimum methadone compliance testing: an evidence-based analysis.
    Medical Advisory Secretariat
    Ont Health Technol Assess Ser; 2006; 6(21):1-54. PubMed ID: 23074492
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical Benefits of Direct-to-Definitive Testing for Monitoring Compliance in Pain Management.
    Gencheva R; Petrides A; Kantartjis M; Tanasijevic M; Dahlin JL; Melanson S
    Pain Physician; 2018 Nov; 21(6):E583-E592. PubMed ID: 30508989
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oral fluid is a viable alternative for monitoring drug abuse: detection of drugs in oral fluid by liquid chromatography-tandem mass spectrometry and comparison to the results from urine samples from patients treated with Methadone or Buprenorphine.
    Vindenes V; Yttredal B; Oiestad EL; Waal H; Bernard JP; Mørland JG; Christophersen AS
    J Anal Toxicol; 2011 Jan; 35(1):32-9. PubMed ID: 21219701
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Positivity rates of drugs in patients treated for opioid dependence with buprenorphine: A comparison of oral fluid and urine using paired collections and LC-MS/MS.
    West R; Mikel C; Hofilena D; Guevara M
    Drug Alcohol Depend; 2018 Dec; 193():183-191. PubMed ID: 30391868
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative evaluation of the accuracy of immunoassay with liquid chromatography tandem mass spectrometry (LC/MS/MS) of urine drug testing (UDT) opioids and illicit drugs in chronic pain patients.
    Manchikanti L; Malla Y; Wargo BW; Fellows B
    Pain Physician; 2011; 14(2):175-87. PubMed ID: 21412372
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Protocol for accuracy of point of care (POC) or in-office urine drug testing (immunoassay) in chronic pain patients: a prospective analysis of immunoassay and liquid chromatography tandem mass spectometry (LC/MS/MS).
    Manchikanti L; Malla Y; Wargo BW; Cash KA; Pampati V; Damron KS; McManus CD; Brandon DE
    Pain Physician; 2010; 13(1):E1-E22. PubMed ID: 20119473
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of urine and oral fluid as matrices for screening of thirty-three benzodiazepines and benzodiazepine-like substances using immunoassay and LC-MS(-MS).
    Smink BE; Mathijssen MP; Lusthof KJ; de Gier JJ; Egberts AC; Uges DR
    J Anal Toxicol; 2006 Sep; 30(7):478-85. PubMed ID: 16959142
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevalence and drug use correlates of inadvertent fentanyl exposure among individuals misusing drugs in seven U.S. states.
    Magura S; Lee-Easton MJ; Abu-Obaid R; Reed P; Allgaier B; Fish E; Maletta AL; Amaratunga P; Lorenz-Lemberg B; Levitas M; Achtyes ED
    J Addict Dis; 2024 Feb; ():1-9. PubMed ID: 38355422
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Replacement of immunoassay by LC tandem mass spectrometry for the routine measurement of drugs of abuse in oral fluid.
    Allen KR; Azad R; Field HP; Blake DK
    Ann Clin Biochem; 2005 Jul; 42(Pt 4):277-84. PubMed ID: 15989728
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oral Fluid and Drug Impairment: Pairing Toxicology with Drug Recognition Expert Observations.
    Truver MT; Palmquist KB; Swortwood MJ
    J Anal Toxicol; 2019 Sep; 43(8):637-643. PubMed ID: 31504595
    [TBL] [Abstract][Full Text] [Related]  

  • 13. LC-MS-MS vs ELISA: Validation of a Comprehensive Urine Toxicology Screen by LC-MS-MS and a Comparison of 100 Forensic Specimens.
    Kahl KW; Seither JZ; Reidy LJ
    J Anal Toxicol; 2019 Oct; 43(9):734-745. PubMed ID: 31424082
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Novel Oral Fluid Assay (LC-QTOF-MS) for the Detection of Fentanyl and Clandestine Opioids in Oral Fluid After Reported Heroin Overdose.
    Griswold MK; Chai PR; Krotulski AJ; Friscia M; Chapman BP; Varma N; Boyer EW; Logan BK; Babu KM
    J Med Toxicol; 2017 Dec; 13(4):287-292. PubMed ID: 28971325
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunoassay-Based Drug Tests Are Inadequately Sensitive for Medication Compliance Monitoring in Patients Treated for Chronic Pain.
    Snyder ML; Fantz CR; Melanson S
    Pain Physician; 2017 Feb; 20(2S):SE1-SE9. PubMed ID: 28226337
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevalence and disposition of drugs of abuse and opioid treatment drugs in oral fluid.
    Cone EJ; Clarke J; Tsanaclis L
    J Anal Toxicol; 2007 Oct; 31(8):424-33. PubMed ID: 17988455
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A multicomponent LC-MS/MS method for drugs of abuse testing using volumetric DBS and a clinical evaluation by comparison with urine.
    Guterstam J; Tavic C; Barosso M; Beck O
    J Pharm Biomed Anal; 2024 Jun; 243():116075. PubMed ID: 38457867
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lower Cutoffs for LC-MS/MS Urine Drug Testing Indicates Better Patient Compliance.
    Krock K; Pesce A; Ritz D; Thomas R; Cua A; Rogers R; Lipnick P; Kilbourn K
    Pain Physician; 2017 Nov; 20(7):E1107-E1113. PubMed ID: 29149155
    [TBL] [Abstract][Full Text] [Related]  

  • 19. KIMS, CEDIA, and HS-CEDIA immunoassays are inadequately sensitive for detection of benzodiazepines in urine from patients treated for chronic pain.
    Darragh A; Snyder ML; Ptolemy AS; Melanson S
    Pain Physician; 2014; 17(4):359-66. PubMed ID: 25054395
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.